In 2023, the digital pathology market share is expected to be valued US$ 7,035.8 million. By 2033, the market is probably going to reach US$ 24,961.8 million. In addition, a 13.5% compound annual growth rate (CAGR) is predicted for the industry between 2023 and 2033.
The development of the digital pathology market is being driven by two major factors: the growing use of advanced analytics in pharmaceutical and medical testing. The market is expanding as a result of the use of analytics by government agencies and healthcare financing companies for fraud detection and claim management.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-124
Surge in R&D in Digital Pathology to Augment Sales in Forthcoming Years
In recent years, the digital pathology industry has increased investments in biosimilar research and development initiatives, primarily for cancer treatment and Covid-19 treatment, which have substantially fuelled the market expansion.
Contract Research Organizations (CROs), in-vitro diagnostics (IVD) laboratories, clinical laboratories, and regulatory consultants are being assigned biosimilar development responsibilities by pharmaceutical corporations. These enterprises are developing in order to provide more cost-efficient solutions to their customers, requiring the use of digital pathology instruments to diagnose, research, and design effective healthcare solutions.
Cancer diagnostic Opens New Avenues for Digital Pathology Companies
Due to the sheer increasing occurrence of cancer, there is an increase in spending on digital pathology equipment. Complications arising from late cancer diagnosis, particularly in the case of blood cancer and lung cancer, necessitate the use of significant capital resources during therapy and diagnosis. The success of digital pathology in research is driving demand for these systems in the cancer research industry. This is also encouraging government investors to invest in digital pathology systems for clinical diagnosis. A significant amount of money is spent on cancer diagnosis and therapy monitoring. This explains why digital pathology solutions are in high demand.
Competitive Landscape
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Huron Technologies International Inc.
- Koninklijke Philips N.V.
- Olympus Corporation
- Hamamatsu Photonics K.K.
- Carl Zeiss AG
- Nikon Corporation
- 3DHISTECH Ltd.
- Hologic Inc.
- PerkinElmer, Inc.
- Visiopharm
- OptraSCAN, Inc.
- Inspirata, Inc.
- Sectra AB
Some of the recent developments in digital pathology market are as follows:
- In May 2021, Leica Biosystems joined the European Society for Digital and Integrative Pathology (ESDIP) to assist pathology labs in developing laboratories in accordance with modern digital pathology instruments.
- In March 2021, Roche inked a comprehensive merger agreement with GenMark Diagnostics to broaden its product and distribution channel for European consumers.
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-124
Key Segments:
Digital Pathology by Product Type:
- Digital Pathology Equipment
- Whole Slide Scanners
- Brightfield Slide Scanners
- Fluorescence Slide Scanners
- Combination Slide Scanners
- Clinical Microscope
- Tissue Microarrays
- Digital Pathology Software
- Image Viewing and Analysis Software
- On-premise
- Cloud-based
- Digital Pathology Information Systems
- On-premise
- Cloud-based
- Digital Pathology Services
- Installation and Integration Services
- Consulting Services
- Maintenance and Validation Services
Digital Pathology by Application:
- Clinical Pathology
- Molecular Diagnostics
- Basic & Applied Research
- Drug Development
- Others
Digital Pathology by End User:
- Hospitals
- Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Forensic Laboratories
- Research Institutes
- Contract Research Organizations (CROs)
- Clinics
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
